^
Association details:
| Biomarker: | TUBB3 expression |
|---|---|
| Cancer: | Peritoneal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Ixempra (ixabepilone) (Microtubule inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Published date:
02/11/2022
Excerpt:
Participants were randomised to receive ixabepilone 20 mg/m2 days 1, 8, 15 with (IXA + BEV) or without (IXA) bevacizumab...Both regimens were well-tolerated. TUBB3 expression did not predict response...TUBB3 is not a predictive biomarker.
DOI:
10.1038/s41416-022-01717-6
Trial ID:
Source:
Title:
Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Published date:
03/19/2021
Excerpt:
The goal of this multi-center randomized phase II study was to assess the activity and safety of ixabepilone with bevacizumab compared to ixabepilone alone in patients with platinum resistant/refractory ovarian, fallopian tube, or primary peritoneal cancer. TUBB3 expression did not predict response in either arm.
